2,5-dihydroxymethyl-3,6-dimethylpyrazine

10/01/2014 - "Liguzinediol improved the heart function and inhibited myocardial cell apoptosis in rats with heart failure."
10/01/2014 - "In this study we investigated the effects of liguzinediol on a rat model of heart failure. "
07/01/2018 - "Liguzinediol (2,5-dihydroxymethyl-3,6-dimethylpyrazine, LZDO) is a potential agent for the low-risk treatment of heart failure. "
01/01/2020 - "The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism."
05/01/2016 - "The purpose of this study was to investigate the effect of a new drug-liguzinediol on cardiac fibrosis of heart failure Male Sprague-Dawley rats (SD) rats and the underlying mechanisms. "

05/01/2016 - "Liguzinediol could be exploited to be a promising candidate for cardiac fibrosis. "
05/01/2016 - "These data collectively indicated that liguzinediol could protect against cardiac fibrosis in rats. "
05/01/2016 - "Liguzinediol decreased cardiac muscle fiber break evidenced by HE staining and it significantly reduced cardiac fibrosis evidenced by Masson staining in DOX-treated rats. "
05/01/2016 - "Liguzinediol protects against cardiac fibrosis in rats in vivo and in vitro."
05/01/2016 - "The purpose of this study was to investigate the effect of a new drug-liguzinediol on cardiac fibrosis of heart failure Male Sprague-Dawley rats (SD) rats and the underlying mechanisms. "

01/01/2020 - "Liguzinediol improved ventricular remodeling by reducing myocardial cell necrosis, as well as reducing collagen deposition and myocardial fibrosis. "

01/01/2020 - "Liguzinediol improved ventricular remodeling by reducing myocardial cell necrosis, as well as reducing collagen deposition and myocardial fibrosis. "

01/01/2020 - "The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism."